Details of the Drug

General Information of Drug (ID: DMB5N7B)

• Drug Name: Modakafusp alfa
• Synonyms: TAK-573

Indication

Disease Entry	ICD 11	Status	REF
Aggressive cancer	2A00-2F9Z	Phase 1/2	[1]
Multiple myeloma	2A83	Phase 1/2	[2]

• Cross-matching ID:
  UNII: TN8CEX4UT2
  DrugBank ID: DB16399
  TTD ID: D1B3VP
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

References

• [1] ClinicalTrials.gov (NCT04157517) An Open-Label, Dose-Escalation Phase 1b/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Modakafusp Alfa (TAK-573) as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced or Metastatic Solid Tumors. U.S.National Institutes of Health.
• [2] ClinicalTrials.gov (NCT05590377) A Phase 1/2a Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Modakafusp Alfa in Combination With Daratumumab Subcutaneous in Patients With Relapsed or Refractory Multiple Myeloma. U.S.National Institutes of Health.